BMS Buys Into Promising Neuropathic Pain Market Via Allergan Deal
This article was originally published in The Pink Sheet Daily
New compound could one day help Bristol tap into a growing area of unmet need in diabetes.
You may also be interested in...
Phase III results with metformin leave some disappointed, while another study hints of niche role in insulin-resistant patients.
AstraZeneca hints that drug could be priced lower than Merck's blockbuster Januvia.
Bristol-Myers Squibb is buying the biotech company Medarex in a deal valued at $2.4 billion, or $16.00 per share in cash, the companies announced July 22. In doing so, Bristol gains full rights to the late-stage cancer drug ipilimumab and to innovative technologies for developing immunology and oncology humanized antibodies